Welcome to our dedicated page for enGene Holdings news (Ticker: ENGN), a resource for investors and traders seeking the latest updates and insights on enGene Holdings stock.
enGene Holdings Inc. (ENGN) is a clinical-stage biotechnology pioneer developing non-viral gene therapies through its proprietary DDX delivery platform. This page serves as the definitive source for verified company news and press releases, providing stakeholders with timely updates on therapeutic advancements and corporate developments.
Investors and researchers will find curated information spanning clinical trial progress, regulatory milestones, and strategic partnerships. Our collection focuses on critical updates including:
- Phase developments for lead candidate EG-70 in bladder cancer treatment
- Innovations in mucosal-targeted gene delivery systems
- Collaborations advancing genetic medicine applications
- Peer-reviewed research publications and conference presentations
Bookmark this page for direct access to primary source materials from enGene, ensuring you stay informed about advancements in localized gene therapy solutions addressing high-need oncological conditions. All content is vetted for accuracy and updated systematically to reflect the company's progress in transforming genetic medicine.
enGene Holdings Inc. (Nasdaq: ENGN) announced an oral presentation at the American Urology Association 2024 Annual Meeting regarding its non-viral gene therapy EG-70 for BCG-unresponsive non-muscle invasive bladder cancer. The presentation highlights the rational design of EG-70 to address challenges faced by other treatment options. Promising Phase 1 data show complete response rates of 70% and 60% at three and six months, respectively, with encouraging safety results.
FAQ
What is the current stock price of enGene Holdings (ENGN)?
What is the market cap of enGene Holdings (ENGN)?
